Little-Known Protein EVA1B Emerges as a Hidden Driver of Lung Cancer Spread

Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for the vast majority of those deaths. Most patients do not succumb to the primary tumor itself but to its ability to grow relentlessly and seed distant organs, particularly the brain, bones, liver, and the other lung. For decades, researchers have hunted for the molecular switches that grant tumor cells this lethal mobility, and each new switch that is identified represents a potential point of therapeutic intervention. Now, a team of investigators at Fujian Cancer Hospital and the Clinical Oncology School of Fujian Medical University in China has added a surprising new name to that list: EVA1B, a little-studied member of the Eva-1 homolog family of proteins. Their study, published in the journal 3 Biotech, suggests that EVA1B helps drive NSCLC progression through a functional partnership with leucine-rich alpha-2-glycoprotein 1, better known in the cancer biology literature as LRG1.

The EVA1 family has been attracting growing attention in recent years, although most of the spotlight has fallen on its siblings. EVA1A has been implicated in autophagy and cell death pathways and has been described as a prognostic biomarker in glioma and hepatocellular carcinoma, while EVA1C has been linked to immune infiltration in low-grade gliomas. EVA1B, by contrast, has remained comparatively obscure, with only a handful of studies hinting at oncogenic roles in colorectal cancer and esophageal squamous carcinoma. The new work is among the first to examine the protein systematically in lung cancer, combining large-scale bioinformatic analysis with hands-on experiments in human tissue samples, cultured cell lines, and animal models.

The investigation began in silico. By mining publicly available genomic datasets, the researchers found that EVA1B and LRG1 display subtype-specific expression patterns across NSCLC, differing between lung adenocarcinoma and squamous cell carcinoma. Crucially, the computational analysis suggested that the two molecules are not merely co-expressed by coincidence but may be functionally connected, a hypothesis that shaped the entire experimental program that followed. This kind of integrative transcriptomic approach has become a standard starting point for biomarker discovery, but the team went well beyond correlation, seeking physical and functional evidence in biological systems.

The first line of experimental evidence came from paired clinical samples obtained from patients at Fujian Cancer Hospital, work that was approved by the institution’s ethics committee with written informed consent from all participants. Using immunohistochemistry and Western blot analysis, the researchers compared tumor tissue with matched paracancerous tissue taken from the same patients. The results were unambiguous: EVA1B protein levels were consistently higher in the tumor specimens. The pattern was mirrored in cell culture, where two NSCLC cell lines, A549 and H1299, both expressed more EVA1B than BEAS-2B, an immortalized but non-malignant bronchial epithelial cell line used as a normal reference. Together, these findings established that EVA1B overexpression is a reproducible feature of NSCLC cells rather than an artifact of any single model system.

With overexpression confirmed, the researchers asked what happens when EVA1B is removed. Using knockdown techniques to suppress the protein in the A549 and H1299 cells, they ran a battery of functional assays designed to probe the hallmarks of malignancy. Proliferation, measured with CCK-8 assays, slowed markedly. Migration, assessed with wound-healing experiments, and invasion, measured with Transwell chambers, were both significantly impaired. In other words, cells stripped of EVA1B became less able to multiply, less able to move, and less able to chew their way through surrounding tissue, the three capabilities that together make a cancer dangerous.

The molecular signature behind these behavioral changes pointed to a well-known process called the epithelial–mesenchymal transition, or EMT, and its malignant cousin, the EMT-like phenotype. During EMT, epithelial cancer cells shed their adhesive, stationary identity and acquire the motile, invasive character of mesenchymal cells, a transformation that is widely regarded as a critical step in metastasis. When EVA1B was knocked down, the cells showed increased expression of E-cadherin, the epithelial marker that keeps cells glued together, and decreased expression of N-cadherin and Vimentin, two classic mesenchymal markers. Levels of matrix metalloproteinase 11, an enzyme that helps degrade the extracellular matrix and clear a path for invading cells, also fell. The coordinated shift in this marker panel indicates that EVA1B helps maintain the invasive, EMT-like state of NSCLC cells.

Cell culture can only say so much, so the team turned to animal models. In xenograft experiments, in which human cancer cells are implanted into immunocompromised mice, tumors with EVA1B knocked down grew significantly more slowly than controls. More strikingly, in a lung metastasis model, silencing EVA1B reduced the metastatic burden in the animals’ lungs, providing direct in vivo evidence that the protein contributes to the spread of disease, not just to growth of the primary tumor. These experiments, approved under the hospital’s animal ethics protocols, bring the findings closer to physiological relevance and strengthen the case that EVA1B is a genuine driver of NSCLC aggressiveness rather than a passive passenger.

The mechanistic heart of the study lies in its connection to LRG1, a secreted glycoprotein whose name reflects a leucine-rich repeat structure and whose levels have long been monitored as an inflammatory marker in clinical blood tests. In recent years, LRG1 has been recast as an active participant in disease, particularly in pathological blood vessel formation and in tumor biology. Previous work by other groups has shown that LRG1 derived from NSCLC cells can be packaged into exosomes and promote angiogenesis through transforming growth factor beta signaling, and that exosomal LRG1 can drive NSCLC proliferation and metastasis by binding the extracellular matrix protein fibronectin. The Fujian team’s bioinformatic analysis had flagged a functional association between EVA1B and LRG1, and co-immunoprecipitation experiments provided supporting evidence: EVA1B and LRG1 were found together in the same immunoprecipitated protein complex, suggesting that the two molecules associate within cells or in closely associated molecular assemblies. The authors are careful in their language, describing an LRG1-associated mechanism rather than claiming a fully defined direct interaction, an appropriate degree of caution given that co-immunoprecipitation detects co-complex membership and does not by itself prove direct physical binding between two purified proteins.

Even with that caveat, the convergence of evidence is compelling. EVA1B is overexpressed in patient tumors and cancer cell lines; removing it suppresses proliferation, migration, invasion, EMT-like marker switching, xenograft growth, and metastatic colonization; and the protein appears to operate in concert with LRG1, a molecule already implicated in NSCLC progression through independent lines of research. If future work confirms and elaborates the EVA1B–LRG1 axis, it could open several therapeutic avenues. LRG1 is a secreted protein, and secreted targets are generally more druggable than intracellular ones, with antibody-based approaches already being explored against LRG1 in ocular disease and cancer settings. Alternatively, EVA1B itself, or the downstream EMT programs it sustains, could serve as a biomarker to identify patients at high risk of metastasis, or as a target for combination strategies alongside existing EGFR inhibitors and immunotherapies, both of which face well-documented resistance problems in NSCLC.

For now, the study stands as a textbook example of how modern cancer biology progresses from computational hint to clinical sample to mechanistic model. It also adds a new branch to the growing tree of EVA1 family research, positioning EVA1B alongside its better-known relatives as a molecule worth watching. Lung cancer kills roughly 1.8 million people each year, and every newly validated node in its signaling network represents another potential vulnerability. The Fujian team’s work, supported by the Natural Science Foundation of Fujian, suggests that a once-overlooked protein and an inflammation-associated glycoprotein may together form one such node, and that dismantling it could help deprive NSCLC of its migratory edge.

Subject of Research: The role of the EVA1B protein and its association with LRG1 in driving non-small cell lung cancer progression and metastasis.

Article Title: EVA1B promotes non-small cell lung cancer progression through an LRG1-associated mechanism

Article References: Huang, Z., Wang, H., Jiang, K., & Zhuang, W. (2026). EVA1B promotes non-small cell lung cancer progression through an LRG1-associated mechanism. 3 Biotech, 16(10), Article 444. https://doi.org/10.1007/s13205-026-05034-0

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05034-0

Keywords: non-small cell lung cancer, EVA1B, LRG1, tumor progression, metastasis, EMT-like phenotype, epithelial-mesenchymal transition, biomarker, xenograft model, co-immunoprecipitation, cancer biology, A549 cells